What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...

Market News Wall Street was closed on Monday for Presidents’ Day. U.S. stocks ended mixed on Friday due to strong earnings and economic data. While the Nasdaq rose, the Dow and the S&P 500 fell. How ...

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) on February 14 and set a price target of $45.00.

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...

Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...

The e-commerce company's Hong Kong stock rallied 6.3% after Bloomberg and Reuters reported that Chinese President Xi Jinping would meet with Alibaba co-founder Jack Ma and other business leaders.

The Dow fell and the Nasdaq Composite rose Nasdaq Friday as the stock market reacted to news of delays to President Donald Trump's reciprocal tariffs.